NervGen Pharma Corp. (NGEN)

NervGen Pharma Statistics

Total Valuation

NervGen Pharma has a market cap or net worth of $206.03 million. The enterprise value is $201.07 million.

Market Cap	206.03M
Enterprise Value	201.07M

Important Dates

The last earnings date was Friday, May 22, 2026.

Earnings Date	May 22, 2026
Ex-Dividend Date	n/a

Share Statistics

NervGen Pharma has 106.20 million shares outstanding. The number of shares has increased by 6.72% in one year.

Current Share Class	106.20M
Shares Outstanding	106.20M
Shares Change (YoY)	+6.72%
Shares Change (QoQ)	+8.69%
Owned by Insiders (%)	1.90%
Owned by Institutions (%)	4.24%
Float	94.18M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	41.66
P/TBV Ratio	57.76
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.34

Current Ratio	1.34
Quick Ratio	1.09
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -1,207.46% and return on invested capital (ROIC) is -473.69%.

Return on Equity (ROE)	-1,207.46%
Return on Assets (ROA)	-90.75%
Return on Invested Capital (ROIC)	-473.69%
Return on Capital Employed (ROCE)	-479.57%
Weighted Average Cost of Capital (WACC)	8.05%
Revenue Per Employee	n/a
Profits Per Employee	-$3.00M
Employee Count	10
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -48.28% in the last 52 weeks. The beta is 0.69, so NervGen Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.69
52-Week Price Change	-48.28%
50-Day Moving Average	3.68
200-Day Moving Average	3.63
Relative Strength Index (RSI)	20.92
Average Volume (20 Days)	1,244,260

Short Selling Information

The latest short interest is 1.56 million, so 1.47% of the outstanding shares have been sold short.

Short Interest	1.56M
Short Previous Month	1.47M
Short % of Shares Out	1.47%
Short % of Float	1.66%
Short Ratio (days to cover)	8.83

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-19.04M
Pretax Income	-29.98M
Net Income	-29.98M
EBITDA	-19.00M
EBIT	-19.04M
Earnings Per Share (EPS)	-$0.40

Balance Sheet

The company has $11.86 million in cash and n/a in debt, with a net cash position of $11.86 million or $0.11 per share.

Cash & Cash Equivalents	11.86M
Total Debt	n/a
Net Cash	11.86M
Net Cash Per Share	$0.11
Equity (Book Value)	3.97M
Book Value Per Share	0.05
Working Capital	3.69M

Cash Flow

Operating Cash Flow	-16.89M
Capital Expenditures	n/a
Depreciation & Amortization	40,320
Net Borrowing	-60,778
Free Cash Flow	-17.04M
FCF Per Share	-$0.16

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

NervGen Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-6.72%
Shareholder Yield	-6.72%
Earnings Yield	-14.08%
FCF Yield	-8.00%

Analyst Forecast

The average price target for NervGen Pharma is $11.21, which is 477.84% higher than the current price. The consensus rating is "Buy".

Price Target	$11.21
Price Target Difference	477.84%
Analyst Consensus	Buy
Analyst Count	6
Revenue Growth Forecast (3Y)	n/a
EPS Growth Forecast (3Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2